Want to see CYVNY full AI Analyst Report?
Top Page
Rating:―N/A
Price Target:―
Action:N/A
Date:―
No summary available
Ceryvyn Therapeutics Limited (CYVNY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.62M
Dividend YieldN/A
Average Volume (3M)4.82K
Price to Earnings (P/E)―
Beta (1Y)-1.24
Revenue Growth-97.37%
EPS GrowthN/A
CountryUS
Employees33
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.16
Shares Outstanding170,997,270
10 Day Avg. Volume5,816
30 Day Avg. Volume4,818
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.00
Price to Sales (P/S)1215.83
P/FCF Ratio-0.94
Enterprise Value/Market Cap-1.56
Enterprise Value/Revenue-82.17
Enterprise Value/Gross Profit126.36
Enterprise Value/Ebitda0.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)$766.42K
Ceryvyn Therapeutics Limited Business Overview & Revenue Model
Company Description
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endot...
How the Company Makes Money
Opthea Limited generates revenue primarily through the development and commercialization of its proprietary therapies. The company's revenue model includes potential income from licensing agreements, partnerships, and future sales of its therapies...
Ceryvyn Therapeutics Limited Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 124.67K | 161.16K | 125.05K | 91.98K | 145.90K |
| Gross Profit | 21.72K | -89.31K | -107.42K | -480.00K | -371.37K |
| EBITDA | -200.02M | -223.30M | -99.01M | -50.14M | -24.92M |
| Net Income | -220.24M | -211.88M | -127.99M | -60.79M | -16.12M |
Balance Sheet | |||||
| Total Assets | 188.79M | 148.19M | 87.32M | 184.36M | 71.89M |
| Cash, Cash Equivalents and Short-Term Investments | 172.47M | 133.99M | 64.90M | 157.43M | 62.02M |
| Total Debt | 141.65M | 272.98K | 0.00 | 150.47K | 265.08K |
| Total Liabilities | 264.60M | 156.98M | 17.55M | 4.16M | 7.08M |
| Stockholders Equity | -75.81M | -8.79M | 69.77M | 180.20M | 64.81M |
Cash Flow | |||||
| Free Cash Flow | -161.05M | -179.34M | -98.39M | -61.08M | ― |
| Operating Cash Flow | -161.02M | -179.30M | -98.37M | -61.06M | -8.24M |
| Investing Cash Flow | -33.49K | -32.64K | -23.32K | 880.07K | 482.83K |
| Financing Cash Flow | 243.73M | 248.70M | 236.62K | 156.76M | 48.06M |
Ceryvyn Therapeutics Limited Technical Analysis
Positive
0.02
Price Trends
0.02
Positive
0.02
Positive
0.03
Positive
Market Momentum
<0.01
Negative
57.26
Neutral
16.20
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYVNY, the sentiment is Positive. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 57.26 is Neutral, neither overbought nor oversold. The STOCH value of 16.20 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CYVNY.
Ceryvyn Therapeutics Limited Risk Analysis
Ceryvyn Therapeutics Limited disclosed 72 risk factors in its most recent earnings report. Ceryvyn Therapeutics Limited reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ceryvyn Therapeutics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $16.34M | -2.04 | -56.96% | ― | -56.64% | 64.88% | |
43 Neutral | $10.87M | -2.68 | -91.37% | ― | 49.09% | 3.91% | |
40 Underperform | $5.14M | -0.09 | -1539.97% | ― | ― | 80.28% | |
40 Underperform | $11.83M | -0.19 | -108.72% | ― | 2.15% | 17.34% | |
27 Underperform | $15.64M | -0.51 | 144.63% | ― | -23.95% | 30.12% |
* Healthcare Sector Average
CYVNY
Ceryvyn Therapeutics Limited
0.03
-3.18
-99.19%
PLUR
Pluri
1.24
-2.66
-68.21%
MRKR
Marker Therapeutics
0.98
>-0.01
-0.71%
SNTI
Senti Biosciences
0.17
-1.86
-91.87%
TCRX
TScan Therapeutics
0.17
-1.77
-91.03%
GDTC
CytoMed Therapeutics Limited
0.92
-1.28
-58.27%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―